Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Mar 05, 2026
|
Xencor’s Cash Runway Threatened as Alexion Declines U.S. Ultomiris Royalties
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
PGEN
Precigen, Inc.
Direct platform and lead asset are gene therapy products, making Biotech - Gene Therapy a core tag.
|
$1.06B |
$3.27
-8.03%
|
|
MBX
MBX Biosciences, Inc. Common Stock
MBX's lead programs are peptide-based therapeutics delivered via a proprietary long-acting Precision Endocrine Peptide (PEP™) platform, i.e., Peptide Therapeutics.
|
$1.05B |
$31.03
-0.89%
|
|
CVAC
CureVac N.V.
CureVac's core focus is oncology immunotherapies and cancer vaccines built on its mRNA platform (Biotech - Oncology).
|
$1.05B |
$4.66
|
|
ERAS
Erasca, Inc.
Erasa is a clinical-stage biotechnology company developing targeted cancer therapies, i.e., Biotech - Oncology.
|
$1.02B |
$3.58
+6.07%
|
|
SANA
Sana Biotechnology, Inc.
Sana's lead platform is HIP-modified cell therapy (ex vivo) for allogeneic cell transplantation.
|
$1.02B |
$3.49
-8.64%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Directly focused on oncology therapeutics; Bicara's lead candidate is an antibody-based cancer therapy.
|
$1.01B |
$18.68
+0.78%
|
|
XERS
Xeris Biopharma Holdings, Inc.
Xeris's XeriSol and XeriJect drug-delivery platforms enable stable, ready-to-use injectable formulations, a core differentiator.
|
$1.01B |
$6.05
-0.25%
|
|
SVRA
Savara Inc.
Molgramostim is a recombinant GM-CSF protein delivered as an inhalation therapy; directly a recombinant protein/enzymes product.
|
$1.00B |
$5.58
-3.79%
|
|
VTYX
Ventyx Biosciences, Inc.
VTX assets are oral small molecule therapeutics for autoimmune/inflammatory diseases (NLRP3 inhibitors).
|
$998.32M |
$14.00
|
|
GHRS
GH Research PLC
GH Research's focus on neuropsychiatric drug development (CNS/psychiatric disorders) via 5-MeO-DMT therapies.
|
$991.85M |
$15.62
-2.28%
|
|
VERV
Verve Therapeutics, Inc.
Verve Therapeutics' core offering is in vivo gene therapy using base editing delivered to liver cells, aligning with Biotech - Gene Therapy.
|
$988.30M |
$11.13
|
|
PCRX
Pacira BioSciences, Inc.
Pacira's pMVL-based Drug Delivery Platforms enable extended-release formulations used in EXPAREL and ZILRETTA.
|
$983.47M |
$22.84
-0.07%
|
|
MRVI
Maravai LifeSciences Holdings, Inc.
Maravai produces highly modified nucleic acids (mRNA, oligonucleotides) and related inputs, including acquisitions expanding DNA/RNA production capabilities.
|
$976.80M |
$3.63
-4.84%
|
|
TBPH
Theravance Biopharma, Inc.
Ampreloxetine is an oral small-molecule therapeutic in Phase 3 (CYPRESS) for symptomatic nOH in MSA, representing a core TBPH pipeline asset.
|
$969.96M |
$19.09
-0.86%
|
|
SDGR
Schrödinger, Inc.
The company operates a proprietary drug discovery pipeline with programs in oncology, aligning with Biotech - Oncology.
|
$966.48M |
$12.88
-1.87%
|
|
CGEM
Cullinan Therapeutics, Inc.
Cullinan develops bispecific antibodies (CD19xCD3 and BCMAxCD3) as core assets.
|
$962.91M |
$15.50
-4.91%
|
|
RAPT
RAPT Therapeutics, Inc.
RAPT's pipeline includes oncology-focused assets under Biotech - Oncology (tivumecirnon) and broader oncology immunotherapy focus.
|
$959.52M |
$57.99
-0.04%
|
|
FTRE
Fortrea Holdings Inc.
Fortrea operates as a standalone contract research organization providing outsourced clinical development services.
|
$959.11M |
$9.89
-4.72%
|
|
OMER
Omeros Corporation
Narsoplimab and zaltenibart OMS906 are monoclonal antibody therapeutics, a core product class for Omeros.
|
$958.91M |
$13.94
-1.10%
|
|
ABUS
Arbutus Biopharma Corporation
Imdusiran is an RNA interference therapeutic (RNAi) targeting HBV, representing the core product category.
|
$948.91M |
$4.58
-7.58%
|
|
URGN
UroGen Pharma Ltd.
ZUSDURI (UGN-102) is an oncology therapeutic developed by UroGen, placing the company in Biotech - Oncology.
|
$943.67M |
$19.01
-5.70%
|
|
GERN
Geron Corporation
Geron directly develops and commercializes RYTELO (imetelstat), an oncology therapeutic indicated for lower-risk MDS.
|
$938.38M |
$1.42
-3.40%
|
|
OPK
OPKO Health, Inc.
ModeX Therapeutics' multi-specific antibodies represent a bispecific antibody product category.
|
$921.24M |
$1.18
-2.08%
|
|
ATAI
Atai Beckley N.V
Acquisition of IntelGenx adds drug delivery platforms (oral thin-film) powering VLS-01 and related assets.
|
$919.51M |
$4.16
-3.03%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Amphastar is advancing biosimilar programs (AMP-004) and positions biosimilars as a core growth pillar.
|
$917.21M |
$20.18
+1.13%
|
|
XNCR
Xencor, Inc.
Company develops and advances bispecific antibodies (XmAb 2+1 formats) for oncology and autoimmune indications.
|
$909.77M |
$11.14
-12.56%
|
|
VALN
Valneva SE
Valneva directly manufactures and sells vaccines (e.g., VLA15 Lyme vaccine, IXCHIQ chikungunya vaccine, IXIARO, DUKORAL) and is advancing multiple vaccine candidates, making vaccines its core product category.
|
$890.75M |
$11.09
+1.09%
|
|
ARVN
Arvinas, Inc.
Lead program ARV-471 (vepdegestrant) is an oncology-focused asset, reflecting Arvinas' core business in cancer therapeutics and PROTAC technology.
|
$883.73M |
$13.53
-1.67%
|
|
JANX
Janux Therapeutics, Inc.
Immunology Therapeutics captures immune-oncology strategies and immune modulation within cancer.
|
$863.12M |
$13.76
-4.15%
|
Showing page 9 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
